Dimensional Fund Advisors’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.01M Buy
1,051,996
+312,945
+42% +$1.42M ﹤0.01% 2489
2026
Q1
$3.33M Sell
739,051
-548,396
-43% -$2.86M ﹤0.01% 2607
2025
Q4
$7.92M Sell
1,287,447
-408,449
-24% -$2.96M ﹤0.01% 2367
2025
Q3
$12.3M Sell
1,695,896
-377,322
-18% -$2.24M ﹤0.01% 2229
2025
Q2
$11M Sell
2,073,218
-139,992
-6% -$827K ﹤0.01% 2242
2025
Q1
$19.6M Sell
2,213,210
-59,145
-3% -$710K ﹤0.01% 1955
2024
Q4
$31.2M Sell
2,272,355
-151,122
-6% -$2.79M 0.01% 1796
2024
Q3
$66.4M Sell
2,423,477
-353,482
-13% -$9.57M 0.02% 1337
2024
Q2
$67.9M Buy
2,776,959
+75,445
+3% +$1.66M 0.02% 1244
2024
Q1
$57.6M Buy
2,701,514
+20,596
+0.8% +$443K 0.02% 1367
2023
Q4
$51.3M Buy
2,680,918
+89,330
+3% +$1.55M 0.02% 1429
2023
Q3
$41.6M Sell
2,591,588
-81,883
-3% -$1.56M 0.01% 1472
2023
Q2
$62M Sell
2,673,471
-50,925
-2% -$1.11M 0.02% 1207
2023
Q1
$63.3M Buy
+2,724,396
New +$55.3M 0.02% 1145
2022
Q3
$46.4M Sell
2,432,450
-108,757
-4% -$2.5M 0.02% 1286
2022
Q2
$46.2M Sell
2,541,207
-19,737
-0.8% -$410K 0.02% 1346
2022
Q1
$64.5M Sell
2,560,944
-74,859
-3% -$1.92M 0.02% 1188
2021
Q4
$72.7M Sell
2,635,803
-50,573
-2% -$1.47M 0.02% 1132
2021
Q3
$86.7M Sell
2,686,376
-82,328
-3% -$2.73M 0.03% 956
2021
Q2
$84.7M Buy
2,768,704
+37,825
+1% +$1.09M 0.03% 996
2021
Q1
$82.9M Sell
2,730,879
-31,158
-1% -$884K 0.03% 993
2020
Q4
$54.6M Sell
2,762,037
-7,910
-0.3% -$128K 0.02% 1294
2020
Q3
$36.1M Sell
2,769,947
-68,230
-2% -$863K 0.02% 1459
2020
Q2
$32.2M Sell
2,838,177
-147,563
-5% -$2.1M 0.01% 1562
2020
Q1
$42.7M Buy
2,985,740
+14,851
+0.5% +$314K 0.02% 1158
2019
Q4
$80.9M Buy
2,970,889
+19,496
+0.7% +$536K 0.03% 916
2019
Q3
$84.5M Buy
2,951,393
+225,317
+8% +$6.57M 0.03% 831
2019
Q2
$75.7M Buy
2,726,076
+105,172
+4% +$2.97M 0.03% 967
2019
Q1
$87M Buy
2,620,904
+87,501
+3% +$2.66M 0.03% 795
2018
Q4
$73.6M Sell
2,533,403
-108,878
-4% -$3.92M 0.03% 830
2018
Q3
$122M Sell
2,642,281
-412,982
-14% -$18.4M 0.05% 540
2018
Q2
$114M Sell
3,055,263
-461,077
-13% -$15.6M 0.05% 552
2018
Q1
$104M Sell
3,516,340
-15,544
-0.4% -$526K 0.04% 598
2017
Q4
$121M Sell
3,531,884
-48,197
-1% -$1.63M 0.05% 489
2017
Q3
$130M Buy
3,580,081
+149,865
+4% +$4.27M 0.06% 417
2017
Q2
$88.6M Buy
3,430,216
+787,396
+30% +$16.7M 0.04% 613
2017
Q1
$50.7M Buy
2,642,820
+987,966
+60% +$17.5M 0.02% 1167
2016
Q4
$27.6M Buy
1,654,854
+204,049
+14% +$3.69M 0.01% 1726
2016
Q3
$29.9M Buy
1,450,805
+2,300
+0.2% +$58.3K 0.02% 1576
2016
Q2
$44.3M Buy
1,448,505
+24,137
+2% +$839K 0.03% 1098
2016
Q1
$53.3M Buy
1,424,368
+83,327
+6% +$3.14M 0.03% 851
2015
Q4
$57.9M Buy
1,341,041
+125,196
+10% +$5.29M 0.04% 722
2015
Q3
$45.6M Buy
1,215,845
+80,662
+7% +$2.86M 0.03% 892
2015
Q2
$38.6M Sell
1,135,183
-1,450
-0.1% -$49.3K 0.02% 1147
2015
Q1
$40.2M Buy
1,136,633
+1,974
+0.2% +$70.7K 0.03% 1060
2014
Q4
$38.6M Buy
1,134,659
+18,522
+2% +$657K 0.03% 1035
2014
Q3
$43M Buy
1,116,137
+7,292
+0.7% +$272K 0.03% 820
2014
Q2
$43.2M Buy
1,108,845
+19,897
+2% +$740K 0.03% 847
2014
Q1
$37.2M Sell
1,088,948
-20,310
-2% -$629K 0.03% 905
2013
Q4
$23.3M Sell
1,109,258
-10,672
-1% -$270K 0.02% 1374
2013
Q3
$26.3M Buy
1,119,930
+244,306
+28% +$6.94M 0.02% 1092
2013
Q2
$23.5M Buy
+875,624
New +$25.4M 0.02% 1089

Other funds holding MYGN

Dimensional Fund Advisors's MYGN Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Myriad Genetics (MYGN) stake by 42% in Q2 2026, buying an estimated $1.42M and bringing the position to 1,051,996 shares worth $6.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2489.

Dimensional Fund Advisors first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $130M in Q3 2017. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Dimensional Fund Advisors held 1,051,996 shares of Myriad Genetics worth $6.01M as of Q2 2026.
  • Dimensional Fund Advisors bought 312,945 Myriad Genetics shares in Q2 2026, an estimated $1.42M.
  • Myriad Genetics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2489 holding.
  • Dimensional Fund Advisors first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Dimensional Fund Advisors's Myriad Genetics position peaked at $130M in Q3 2017.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.